Literature DB >> 32029913

Elevated blood pressure-associated cardiometabolic risk factors and biomarkers in 16-23 years old students with or without metabolic abnormalities.

Katarína Šebeková1, Radana Gurecká2,3, Melinda Csongová2, Ivana Koborová2, Jozef Šebek4.   

Abstract

In obesity, cardiometabolic risk markers show worsening trends with increasing blood pressure (BP). We assumed that risk markers show similar trends across BP categories (normotension, high normal BP, hypertension) in metabolic abnormalities-free subjects (without obesity, insulin resistance, atherogenic dyslipidemia, hyperuricemia, microinflammation) and those presenting them. Data from 2547 (48.1% males) subjects aged 16-23 years were analyzed. The prevalence of males increased across BP categories. Forty-seven percent of individuals with elevated BP were metabolic abnormalities-free. Among 1461 metabolic abnormalities-free subjects, 9% had high normal BP, and 4% hypertension; among 1086 individuals presenting metabolic abnormalities, the prevalence reached 13% and 6%, respectively, (p < 0.001). Both groups displayed similar BP values in corresponding BP categories and significant trends in markers of adiposity, insulin resistance, HDL-cholesterol, atherogenic index of plasma, uric acid, adiponectinemia, and antioxidant capacity of plasma across BP categories. In metabolic abnormalities-free individuals, also significant trends in soluble receptors for advanced glycation end products were revealed. Continuous metabolic syndrome score, a measure of cardiometabolic risk, increased across BP categories regardless of presence or absence of metabolic abnormalities. Multivariate regression models selected male gender, fat-free mass, and uric acid as significant independent predictors for determining BP. Our data emphasize that having a BP outside the normal range significantly worsens risk for cardiometabolic disease in young individuals even if the thresholds for any of the risk factors are not exceeded. Longitudinal studies are needed to assess whether in patients with elevated BP the prognosis of adverse outcomes differs between those presenting and not presenting metabolic abnormalities.

Entities:  

Year:  2020        PMID: 32029913     DOI: 10.1038/s41371-020-0309-5

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  3 in total

1.  Childhood risk factors for high adult blood pressure: the Muscatine Study.

Authors:  R M Lauer; W R Clarke
Journal:  Pediatrics       Date:  1989-10       Impact factor: 7.124

2.  Continuous metabolic syndrome score (siMS) enables quantification of severity of cardiometabolic affliction in individuals not presenting with metabolic syndrome.

Authors:  K Sebekova; J Sebek
Journal:  Bratisl Lek Listy       Date:  2018       Impact factor: 1.278

Review 3.  Development of hypertension in overweight adolescents: a review.

Authors:  Rebecca K Kelly; Costan G Magnussen; Matthew A Sabin; Michael Cheung; Markus Juonala
Journal:  Adolesc Health Med Ther       Date:  2015-10-21
  3 in total
  3 in total

1.  Effects of High Flux Hemodialysis Combined with L-Carnitine on Microinflammation and Arteriovenous Fistula in Maintenance Hemodialysis Patients.

Authors:  Yunhong Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

2.  Sex Differences in Association of Elevated Blood Pressure with Variables Characterizing Cardiometabolic Risk in Young Subjects with or Without Metabolic Abnormalities.

Authors:  Katarína Šebeková; Radana Gurecká; Melinda Csongová; Ivana Koborová; Jozef Šebek
Journal:  Int J Environ Res Public Health       Date:  2020-05-21       Impact factor: 3.390

3.  Fat-free/lean body mass in children with insulin resistance or metabolic syndrome: a systematic review and meta-analysis.

Authors:  Diana Paola Córdoba-Rodríguez; Iris Iglesia; Alejandro Gomez-Bruton; Gerardo Rodríguez; José Antonio Casajús; Hernan Morales-Devia; Luis A Moreno
Journal:  BMC Pediatr       Date:  2022-01-22       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.